CACrown ArchivesThe cinema collection
Menu
Research dossier · General Reference

Serotonin receptor agonist

endogenous compounds and drugs that bind to and activate serotonin receptors

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionJul 8, 2026
Entity authorityQ7455050 ↗
Source-derived summary

A serotonin receptor agonist is an agonist of one or more serotonin receptors. They activate serotonin receptors in a manner similar to that of serotonin (5-hydroxytryptamine; 5-HT), a neurotransmitter and hormone and the endogenous ligand of the serotonin receptors.

Non-selective agonists

Serotonergic psychedelics such as tryptamines (e.g., psilocybin, psilocin, DMTTooltip dimethyltryptamine, 5-MeO-DMT, bufotenin), lysergamides (e.g., LSDTooltip lysergic acid diethylamide, ergine (LSA)), phenethylamines (e.g., mescaline, 2C-B, 25I-NBOMe), and amphetamines (e.g., MDATooltip 3,4-methylenedioxyamphetamine, DOMTooltip 2,5-dimethoxy-4-methylamphetamine) are non-selective agonists of serotonin receptors. Their hallucinogenic effects are specifically mediated by activation of the 5-HT2A receptor.

Drugs that increase extracellular serotonin levels such as serotonin reuptake inhibitors (e.g., fluoxetine, venlafaxine), serotonin releasing agents (e.g., fenfluramine, MDMATooltip methylenedioxymethamphetamine), and monoamine oxidase inhibitors (e.g., phenelzine, moclobemide) are indirect non-selective serotonin receptor agonists. They are used variously as antidepressants, anxiolytics, antiobsessionals, appetite suppressants, and entactogens.

5-HT1 receptor agonists

5-HT1A receptor agonists

Azapirones such as buspirone, gepirone, and tandospirone are 5-HT1A receptor partial agonists marketed primarily as anxiolytics, but also as antidepressants. The antidepressants vilazodone and vortioxetine are 5-HT1A receptor partial agonists. Flibanserin, a drug used for female sexual dysfunction, is a 5-HT1A receptor partial agonist. Many atypical antipsychotics, such as aripiprazole, asenapine, clozapine, lurasidone, quetiapine, and ziprasidone, are 5-HT1A receptor partial agonists, and this action is thought to contribute to their beneficial effects on negative symptoms in schizophrenia.

Editorial summary

The public source identifies “Serotonin receptor agonist” as endogenous compounds and drugs that bind to and activate serotonin receptors. This brief keeps that definition visible, then builds a research path around Serotonin, receptor and agonist.

Editorial reviewA practical starting point whose main value is the path it opens into stronger specialist and primary sources. The current 220-word lead offers orientation but no explicit four-digit date, so chronology should not be assumed. The selected authority fields contribute no independent date. Its value is orientation rather than verdict, with Serotonin, receptor and agonist providing the first useful test.
Editorial analysis

Why this record matters

A short description can identify a subject without explaining its stakes. For “Serotonin receptor agonist”, the useful work is to connect “endogenous compounds and drugs that bind to and activate serotonin receptors” to the records capable of establishing context and consequence.

Evidence profile

Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jul 8, 2026. The linked authority identifier is Q7455050. None of the 0 selected statements returned an explicit reference.

Critical limits

Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Serotonin receptor agonist”, its source revision and the description used here.
  2. Expand the search: follow Serotonin receptor agonist primary sources, Serotonin receptor agonist archive and Serotonin research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Serotonin receptor agonist”?
  2. Which cited source is closest to the event, object or claim?
  3. Which institution is responsible for the underlying evidence?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Serotonin receptor agonist” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.